PHARMACY

Thompson unveils Medstat v4.0 platform for health care integration

BY Drew Buono

STAMFORD, Conn. Thomson Healthcare has unveiled its new product, the Medstat Advantage Suite 4.0. This new product will enable large employers, health plans and government agencies to combine health care claims and other information from diverse sources and then enhance analyze the data to improve management.

Medstat 4.0 allowed users to easily integrate various Thomson Healthcare applications and data within their own system. It also allows users to access Thomson analytic and reporting applications through a single sign-on and offers a single, easy to read screen that arranges all the information for the user to view.

According to Jon Newpol, Thomson Healthcare executive vice president, “With these new capabilities, Medstat Advantage Suite will continue to be a powerful tool for employers, health plans and government agencies striving to reduce the cost and improve the quality of healthcare.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Eli Lilly introduces its third new insulin pen in the past year

BY Drew Buono

INDIANAPOLIS Eli Lilly today launched its new insulin pen, KwikPen, which is prefilled with the Humalog brand of insulins. This is the third new insulin pen launched by the company in the last 12 months, following the launches of HumaPen MEMOIR, a digital insulin pen and HumaPen LUXURA, a reusable pen for people who need insulin dosing in smaller increments.

KwikPen is now available by prescription in pharmacies prefilled with the Humalog brand of insulins, including Humalog, Humalog Mix75/25 and Humalog Mix50/50. Patients using the original Humalog and Humalog Mixtures prefilled pen do not need to convert at this time.

“KwikPen, prefilled with Humalog and Humalog Mixtures, provides people with diabetes an exciting new option for accurate insulin dosing with the convenience of an easy-to-use prefilled pen,” said Matt Beebe, Humalog brand leader, Lilly USA.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Pfizer to acquire Encysive, will gain rights to Thelin

BY Drew Buono

NEW YORK Pfizer has announced that it intends on buying Encysive Pharmaceuticals for about $195 million, according to the Associated Press.

As part of the deal, Pfizer would gain the rights to Encysive’s drug Thelin, which is approved in some European countries for the treatment of high blood pressure in the pulmonary artery. The drug is still awaiting approval in the U.S. Pfizer would also gain access to the rest of Encysive’s portfolio of drugs.

Pfizer already markets Revatio for high blood pressure in the pulmonary artery and Thelin would only strengthen the market for the company. Pfizer plans on conducting a late-stage trial of Thelin in the U.S. in hopes of obtaining final approval from the Food and Drug Administration.

Analysts project the drug could make about $100 million annually by 2012.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?